Tivozanib
- Generic Name
- Tivozanib
- Brand Names
- Fotivda
- Drug Type
- Small Molecule
- Chemical Formula
- C22H19ClN4O5
- CAS Number
- 475108-18-0
- Unique Ingredient Identifier
- 172030934T
- Background
Renal cell carcinoma (RCC) is responsible for 3% of cancer cases and is one of the 10 most common cancers in adults. The average age of diagnosis is between age 65 to 74. Tivozanib, also known as FOTIVDA, is a kinase inhibitor developed to treat adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) after prior failed systemic therapi...
- Indication
适用于治疗既往两种或多种全身治疗后复发或难治性晚期肾细胞癌（RCC）的成年患者。
- Associated Conditions
- Advanced Renal Cell Carcinoma, Renal Cell Carcinoma (RCC)
- Associated Therapies
- -
A Phase 1 Study to Evaluate The Effect of Ketoconazole on the Pharmacokinetics of Tivozanib in Healthy Subjects
- First Posted Date
- 2011-06-02
- Last Posted Date
- 2012-06-05
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT01363778
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc., Madison, Wisconsin, United States
A Single Center, Open-label, Randomized, Two-period Crossover Food Effect Study of Single Doses of Tivozanib (AV-951) in Healthy Subjects
- First Posted Date
- 2011-03-16
- Last Posted Date
- 2012-06-05
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT01316848
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc., Dallas, Texas, United States
A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma
- First Posted Date
- 2011-02-16
- Last Posted Date
- 2020-10-27
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Target Recruit Count
- 105
- Registration Number
- NCT01297244
- Locations
- 🇺🇸
David Geffen School of Medicine at UCLA, Los Angeles, California, United States
🇺🇸Southern Cancer Center, Mobile, Alabama, United States
🇺🇸Cancer Center of Kansas, Wichita, Kansas, United States
A Cardiac Safety Study of Tivozanib to Evaluate the Electrocardiogram and Pharmacokinetic-Electrocardiogram Dynamics in Subjects With Advanced Solid Tumors
- First Posted Date
- 2010-09-29
- Last Posted Date
- 2011-09-26
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT01210846
- Locations
- 🇺🇸
Associates in Oncology/Hematology, Rockville, Maryland, United States
🇺🇸Tennessee Onocology, Nashville, Tennessee, United States
🇺🇸Oklahoma University Cancer Institute (OUCI), Oklahoma City, Oklahoma, United States
An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301).
- First Posted Date
- 2010-02-25
- Last Posted Date
- 2020-10-05
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Target Recruit Count
- 277
- Registration Number
- NCT01076010
- Locations
- 🇨🇱
Site 122, Santiago, Chile
🇷🇴Site 441, Bucharest, Romania
🇺🇦Site 496, Donetsk, Ukraine
RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer
- First Posted Date
- 2010-01-29
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 56
- Registration Number
- NCT01058655
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.